AstraZeneca PLC
AZN
Updated: 24/09/2026, 10:15:07
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
No summaries found.
- Share price
- $163.33
- Market cap
- $253.30B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Pascal Claude Roland Soriot
- Employees
- 96,100
- IPO date
- 12/05/1993
- Beta
- 0.211
- Last dividend
- $0.00
- Day range
- $163.33 – $167.59
- 52-week range
- $145.80 – $212.71
- 1-day performance
- -2.99%
- 1-year performance
- 12.02%
- Current drawdown (1Y)
- -23.21%
- CIK
- 0000901832
- CUSIP
- G0593M107
- ISIN
- GB0009895292
- Created
- 07/12/2025, 02:54:09
- Last update
- 24/09/2026, 10:15:07
Track AstraZeneca PLC with an AI analyst
See which prediction-market events move AZN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
Zacks Investment Research • STOCK • 11/06/2026, 21:17:04
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
Reuters • STOCK • 08/06/2026, 18:16:41
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
CNBC • STOCK • 05/06/2026, 20:26:16
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
Zacks Investment Research • STOCK • 03/06/2026, 13:11:06
Leading Bank maintains sell on AstraZeneca at 11,500p as ASCO glow fails to resolve key pipeline questions
Proactive Investors • STOCK • 03/06/2026, 08:41:36
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
Proactive Investors • STOCK • 01/06/2026, 12:02:40
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Fool - Investing News • STOCK • 31/05/2026, 12:19:50
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial
Proactive Investors • STOCK • 29/05/2026, 12:43:16
CelLBxHealth signs master services agreement with AstraZeneca
Proactive Investors • STOCK • 29/05/2026, 04:30:09
FDA Extends Review Time for AZN's Camizestrant Combo in Breast Cancer
Zacks Investment Research • STOCK • 27/05/2026, 13:01:09
US FDA extends review of AstraZeneca's experimental breast cancer pill
Reuters • STOCK • 27/05/2026, 04:23:17
How Big Pharma Is Turning Industrial Heat Into A Strategic Asset
Forbes • STOCK • 26/05/2026, 11:41:18